OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch repair colorectal cancer in China
Yue Ma, Jiting Zhou, Yuxin Ye, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
Yue Ma, Jiting Zhou, Yuxin Ye, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
Showing 5 citing articles:
Cost-effectiveness analysis of FOLFOXIRI/FOLFOXIRI and mFOLFOX6/FOLFIRI treatment in first-line and second-line chemotherapy for metastatic colorectal cancer
Xianglian Li, Jianan Bao, Jingjing Ma
BMJ Open (2025) Vol. 15, Iss. 3, pp. e086372-e086372
Open Access
Xianglian Li, Jianan Bao, Jingjing Ma
BMJ Open (2025) Vol. 15, Iss. 3, pp. e086372-e086372
Open Access
Matching-Adjusted Indirect Comparison Studies in Oncology: A Scoping Review Focused on Reporting Quality
Cecília Menezes Farinasso, Vinícius Lins Ferreira, Flávia Cordeiro Medeiros, et al.
Value in Health Regional Issues (2025) Vol. 47, pp. 101088-101088
Open Access
Cecília Menezes Farinasso, Vinícius Lins Ferreira, Flávia Cordeiro Medeiros, et al.
Value in Health Regional Issues (2025) Vol. 47, pp. 101088-101088
Open Access
Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States
Andong Li, Meiyu Wu, Ouyang Xie, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Andong Li, Meiyu Wu, Ouyang Xie, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Cost-effectiveness analysis of fruquintinib in Chinese patients with refractory metastatic colorectal cancer
Zijia Huang, Lingyan Zhou, Hanrui Zheng, et al.
International Journal of Clinical Pharmacy (2024) Vol. 46, Iss. 4, pp. 872-880
Closed Access | Times Cited: 1
Zijia Huang, Lingyan Zhou, Hanrui Zheng, et al.
International Journal of Clinical Pharmacy (2024) Vol. 46, Iss. 4, pp. 872-880
Closed Access | Times Cited: 1
Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer
Jiayun Zhong, Yu Liu, Fu Qian, et al.
Cancer Management and Research (2024) Vol. Volume 16, pp. 593-602
Open Access
Jiayun Zhong, Yu Liu, Fu Qian, et al.
Cancer Management and Research (2024) Vol. Volume 16, pp. 593-602
Open Access
